Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1 1

Status

Unknown 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Colorectal Neoplasms 215Rectal Neoplasms 85Colonic Neoplasms 76Stomach Neoplasms 56Pancreatic Neoplasms 44Neoplasm Metastasis 40Esophageal Neoplasms 37Neoplasms 28Lung Neoplasms 27Carcinoma, Non-Small-Cell Lung 20Small Cell Lung Carcinoma 19Adenocarcinoma Of Esophagus 19Glioblastoma 18Glioma 17Neuroblastoma 16Esophageal Squamous Cell Carcinoma 16Brain Neoplasms 16Breast Neoplasms 15Sarcoma 11Gliosarcoma 10Biliary Tract Neoplasms 10Central Nervous System Neoplasms 9Astrocytoma 8Adenocarcinoma 8Oligodendroglioma 7Medulloblastoma 7Colorectal Cancer Metastatic 7Rhabdomyosarcoma 6Recurrence 6Locally Advanced Rectal Cancer 6

Interventions

titanium silicide 1mitazalimab 1irinotecan sucrosofate 1devimistat 1S 1 (combination) 1PEGPH20 1Oxaliplatin 1Irinotecan 1Gemcitabine 1Escitalopram 1Albumin-Bound Paclitaxel 1130-nm albumin-bound paclitaxel 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × Pancreatic Ductal Adenocarcinoma × Irinotecan × Clear all
NCT03316326 2017-10-20

S-1, Irinotecan, and Oxaliplatin in Locally-Advanced Pancreatic Cancer

National Taiwan University Hospital

Phase 2 Unknown
35 enrolled
Gastrointestinal

Pancreatic Ductal Adenocarcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡